stockrow
Saturday 7 November 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022.
- EPS
- +88.5%
- Free cash flow
- +9.77%
Quarter to June 2026, against a year earlier
3.53
0.05
+1.44%
Follow UNCY
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 1 | — | — | — | (29.0%) | 1 | 139 | 547 | +1,898.0% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 100.00 | 100.00 | — | — | 0.00 | +100.0 pt | ||||||
| EBT | — | — | (1) | (2) | (2) | (10) | (18) | (31) | (37) | (27) | (35) | +57.2% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,898.84) | (4,525.04) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (1) | (2) | (2) | (10) | (18) | (31) | (37) | (27) | (35) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.63 | 0.28 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.07) | (2.67) | (2.66) | (8.60) | (12.00) | (12.80) | (5.60) | (1.67) | (1.61) | +57.3% | ||||||
| Cash flow | — | — | (0.05) | (1.45) | (1.72) | (4.94) | (10.39) | (7.45) | (4.27) | (1.97) | (1.03) | +68.6% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.05) | (1.45) | (1.72) | (4.96) | (10.40) | (7.46) | (4.28) | (1.97) | (1.03) | +68.7% | ||||||
| Book value | — | — | (0.08) | (1.09) | (3.14) | 14.12 | (0.31) | (1.55) | 1.11 | 1.90 | 1.98 | n/m | ||||||
| Shares, m | — | — | 15 | 1 | 1 | 1 | 2 | 2 | 7 | 16 | 21 | +0.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | — | — | 1.78 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | (0.46) | (1.17) | — | — | (1.21) | (0.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (1) | (1) | (1) | (6) | (16) | (18) | (29) | (31) | (28) | +69.6% | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | (4.6%) | ||||||
| Free cash flow | — | — | (1) | (1) | (1) | (6) | (16) | (18) | (29) | (31) | (28) | +69.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | (1) | (1) | (3) | 16 | (1) | (4) | 7 | 30 | 53 | n/m | |||||
| Net debt | — | — | 1 | 0 | 1 | (17) | 0 | (10) | (26) | (41) | (61) | n/m | ||||||
| Shareholders’ equity | — | — | (1) | (1) | (3) | 16 | 0 | (4) | 7 | 30 | 53 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (7,724.14) | (9,020.83) | (2,030.49) | (105.73) | (167.50) | (369.35) | (164.96) | (65.73) | (69.05) | +7,658.4 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 0.00 | 207.18 | 127.37 | (145.04) | (225.47) | 1,469.52 | (2,088.57) | (141.14) | (101.07) | (141.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 1 | 9 | 12 | 14 | 23 | 22 | — | +85.6% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.08 | 0.05 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Mar 2023 · fundamentals updated 26 Oct 2026
Unicycive Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OKUR OnKure Therapeutics, Inc. | $102.3M | — (loss-making) | — | — | n/m | +22.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMUX Immunic, Inc. | $99.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $98.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| UNCY Unicycive Therapeutics, Inc. | $96.9M | — (loss-making) | — (loss-making) | — | n/m | +9.77% (above 0%: growing) | 0.00% | 0.00% | |
| PMVP PMV Pharmaceuticals, Inc. | $96.3M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDTX Black Diamond Therapeutics, Inc. | $95.4M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LENZ LENZ Therapeutics, Inc. | $94.6M | — (loss-making) | — (loss-making) | −72.93% (below 0%: shrinking) | n/m | −147.16% (below 0%: shrinking) | 86.58% | (972.75%) | Compare |
| VANI Vivani Medical, Inc. | $93.8M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | — (loss-making) | −85.33% (below 0%: shrinking) | n/m | −57.23% (below 0%: shrinking) | 100.00% | (162.74%) | Compare |
| Median of peers | $95.8M | — | — | −72.93% | — | −13.20% | 19.35% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
6.03%
Entities affiliated with Nantahala Capital Management, LLC
9.99%
RA Capital Healthcare Fund, L.P.
9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement